World

North Korea says it tested sea-to-surface cruise missiles

Jan 27, 2025

Seoul [South Korea], January 27: North Korea has tested sea-to-surface strategic cruise guided missiles, Pyongyang's state media reported on Sunday.
State-controlled KCNA news agency quoted the country's Missile Administration as stating the test-fire, held on Saturday, went as planned. It added that ruler Kim Jong Un oversaw the launch.
The test-fire was "part of plans for building the national defence capabilities to raise the effectiveness of strategic control against potential enemies in conformity with the changing regional safety circumstances," KCNA reported.
"The test-fire had no negative impact on the security of the neighbouring countries," it added.
In a separate statement on Sunday, the country's Foreign Ministry criticized the United States and South Korea over recent joint military drills.
The ministry warned the US such moves would be met with "the toughest counteraction," as long as Washington denied the country's sovereignty and security, the statement, carried by KCNA, said.
Pyongyang has significantly expanded its missile tests over the past two years, while sharpening its rhetoric against the US and South Korea. It has also strengthened its military cooperation with Russia.
Source: Qatar Tribune

More news

Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial

Tampa (Florida) [US], November 2: Sirolimus-coated balloon (SCB) strategy was non-inferior to contemporary everolimus-eluting stents (EES) for Target Lesion Failure (TLF) at 12 months in patients with de novo coronary artery disease. These are the results of the TRANSFORM II randomised trial, presented today as a Late-Breaking Clinical Trial at TCT 2026 and accepted in The Lancet which confirm how MagicTouch Sirolimus Coated Balloon (Concept Medical) matches contemporary best in class stent. Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease.

Nov 02, 2026